Prev MonthPrev Month Next MonthNext Month
Webinar: Getting to Know the New JAKs on the Block: Pharmacy-Focused Insights for Atopic Dermatitis and Alopecia Areata
Tuesday, September 14, 2021, 12:00 PM - 1:00 PM MDT
Category: Webinar

Bonus Webinar for CPS Members Only!

Join us for a complimentary CPE/CME Webinar! REGISTER NOW! Boston University School of Medicine’s Webinar Presentation at: Colorado Pharmacists Society

Sept. 14, 2021 from 12 p.m. to 1 p.m.

Activity Description:
Led by a faculty team of specialty pharmacy and dermatology experts, this curriculum will provide targeted education to community pharmacists for the emerging therapies on the horizon in moderate-to-severe atopic dermatitis (AD) and alopecia areata (AA). The presentation will provide discussion around the connection between AD and AA, the role of Janus Kinase (JAK)-signal transducer activator of transcription pathways in the pathogenesis of AD and AA, the latest clinical trial data on emerging agents, racial and health disparities in patients with AA and AD, and the unique role of the pharmacist in providing education and obtaining prior authorization to medications. Utilizing video interviews with actual patients, you will gain greater awareness and empathy for the significant quality of life burden that patients who have these conditions encounter on a daily basis. This program has been thoughtfully crafted to be interactive and will include engaging discussions, valuable teaching points, and ample opportunity for Q&A with leading experts.

Learning Objectives:

  1. Explore the changing paradigm of AA and AD disease presentation and treatment approach.
  2. Assess and interpret the latest clinical trial data among emerging oral agents in AA and/or AD and terms of therapeutic target, safety, efficacy, and tolerability.
  3. Recognize the potential place in therapy and monitoring aspects for the emerging agents in AD and AA in order to effectively engage patients in shared decision-making for their treatment plan.
  4. Outline a plan to proactively identify and remove barriers for health maintenance services and medication access in underserved patients with AA and/or AD.

Target Audience
This curriculum is intended for a broad audience of community pharmacists, dermatologic specialty pharmacists, and managed care professionals involved in the care and treatment of patients with AD and/or AA.

Amanuel Kehasse, PharmD
Course Director
Clinical Pharmacy Specialist
Clinical Pharmacy Specialist in Autoimmune and Interstitial lung disease
Boston Medical Center Health System Boston, MA
Peter A Lio, MD
Assistant Professor of Clinical Dermatology and Pediatrics
Northwestern Feinberg School of Medicine Director, Chicago Integrative Eczema Center Founding Partner
Medical Dermatology Associates of Chicago Chicago, IL




The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This is an application-based educational activity. Pharmacists will receive 1.0 contact
hours (0.10 ceus) for the educational activity. No partial credit is available. ACPE Universal Activity Number (UAN): 0060-9999-21-023-L01-P

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is presented by Boston University School of Medicine and The University of Rhode Island College of Pharmacy and is supported by and independent educational grant from Pfizer.